---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-041102"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:33:47.798027+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech reports updated VERSATILE-002 trial data: mOS 30 months, ORR 36%

## Summary
- Median overall survival 30 months vs published 12-18 months for pembrolizumab alone.
- Objective response rate 36% (19/53); disease control rate 77% (41/53).
- 21% of patients (11/53) had 90-100% tumor shrinkage; 9% (5/53) complete response.
- Phase 3 VERSATILE-003 trial comparing combo vs pembrolizumab monotherapy planned to start in 2024.
- Treatment well tolerated; Grade ≥3 AEs in 9 patients (Grade 3 n=8, Grade 4 n=1).

## SEC filing metadata
- accession: 0001140361-24-041102
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036124041102/0001140361-24-041102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036124041102/ef20035887_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-041102
- JSON: https://secwatch.observer/filing/0001140361-24-041102.json
- Plain text: https://secwatch.observer/filing/0001140361-24-041102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.